Teclison Announces Publication of Phase 1 Data Demonstrating the Safety and Therapeutic Potential of Tirapazamine Chemoembolization for Patients with Unresectable Liver Cancer
PRINCETON, N.J., and TAIPEI, Taiwan, June 21, 2022 (GLOBE NEWSWIRE) -- Teclison, a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, today announced the peer-reviewed publication of a study demonstrating the safety, tolerability and preliminary efficacy of its trans-arterial tirapazamine chemoembolization (TATE) therapy in patients with unresectable early- and intermediate-stage hepatocellular carcinoma (HCC), also known as liver cancer. The clinical data, published in The Journal of Vascular and Interventional Radiology titled “Phase I Dose-Escalation Study of Tirapazamine Chemoembolization for Unresectable Early- and Intermediate-Stage Hepatocellular Carcinoma,” establishes tirapazamine, a hypoxia-activated anti-cancer drug, as safe when administered in conjunction with trans-arterial embolization with promising efficacy in patients with liver cancer, including those with progression or recurrence after treatment with conventional trans-arterial chemoembolization (TACE).
- The current standard of care for unresectable liver cancer is conventional trans-arterial chemoembolization with the chemotherapeutic agent doxorubicin.
- The results of this study support tirapazamine as an alternative to doxorubicin in trans-arterial chemoembolization.
- Seventeen patients with unresectable early-stage HCC or unresectable intermediate-stage HCC were enrolled in this non-randomized, open-label Phase 1 study.
- A Phase 2 randomized study comparing efficacy of TATE vs TACE in patients with intermediate liver cancer is underway.